SCHEMBL23748138

SCHEMBL23748138

C=CCCc1cnccc1C(O)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.44
GAA P10253 1/20 0.38
LMNA P02545 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
KCNA5 P22460 2/20 0.33
KCNH2 Q12809 1/20 0.33
CYP17A1 P05093 1/20 0.33
CFTR P13569 2/20 0.33
GOPC Q9HD26 2/20 0.33
SLC6A2 P23975 2/20 0.33
SLC6A4 P31645 2/20 0.33
SLC6A3 Q01959 2/20 0.33
CYP2C19 P33261 2/20 0.33
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32
ALDH1A1 P00352 1/20 0.32
OPRD1 P41143 1/20 0.32
EPHX2 P34913 1/20 0.32
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23748259 0.89 SMN1; SMN2 (0.44) SMN1; SMN2GAALMNAL3MBTL1KCNA5
SCHEMBL23748180 0.83 KCNA5 (0.33) SMN1; SMN2KCNA5KCNH2CFTRGOPC
SCHEMBL23748324 0.83 CYP3A4 (0.36) SMN1; SMN2GAALMNAL3MBTL1CYP17A1
SCHEMBL23748253 0.82 MEN1 (0.39) SMN1; SMN2LMNASLC6A2SLC6A4SLC6A3
SCHEMBL3062558 0.79 SMN1; SMN2 (0.51) SMN1; SMN2GAALMNAL3MBTL1KCNA5
SCHEMBL28092338 0.75 SMN1; SMN2 (0.47) SMN1; SMN2GAALMNAL3MBTL1KCNA5
SCHEMBL23748286 0.75 KCNA5 (0.33) SMN1; SMN2KCNA5KCNH2CFTRGOPC
SCHEMBL23748218 0.73 SMN1; SMN2 (0.38) SMN1; SMN2GAALMNAL3MBTL1SLC6A2
SCHEMBL24834940 0.71 SMN1; SMN2 (0.43) SMN1; SMN2GAALMNASLC6A4CYP11B1
SCHEMBL8509369 0.71 GABRA1 (0.35) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
EP-3864020-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS Janssen BioPharma, Inc. (US) 2021-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS ACE, PNP, FEN1 SMN1; SMN2 3508/4885GAA 225/4885LMNA 1057/4885
US-11312727-B1 Macrocyclic flu endonuclease inhibitors ACE, FEN1, PNP SMN1; SMN2 3520/4885GAA 200/4885LMNA 965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.